ONC Stock — BeOne Medicines AG

BeOne Medicines AG (ONC)

Updated October 16, 2026.

ONC is a Stock. Total return is 1203.2% over the past 10.7 years, 828.8 points ahead of SPY at 374.4%.

BeOne Medicines AG is an oncology company that discovers and develops cancer treatments, with commercial-stage products including BRUKINSA (a BTK inhibitor for blood cancers), TEVIMBRA (an anti-PD-1 immunotherapy), and several other therapies across solid tumors and blood cancers, alongside a pipeline of clinical and preclinical candidates. The company does not currently distribute to shareholders. BeOne appeals to growth-oriented investors focused on biopharmaceutical development rather than income generation.

ONC performance versus SPY

Price and return data through 2026-10-16.

Total return is 1203.2% over the past 10.7 years, 828.8 points ahead of SPY at 374.4%. Over the past year its total return — price change plus distributions reinvested — is 16.1%. Its deepest 1-year drawdown was 31.0%.

ONC key facts

Asset type

Stock

Asset class

Equity

Inception date

02/03/2016

Distribution frequency

None

Last close

$369.06 (as of 2026-10-16)

Market cap

$38,721,071,772

Average volume

422233.0

Beta

0.609

Payout ratio

0.0%

P/E ratio

66.02

Forward P/E

35.2113

EPS

$5.59

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ONC risks and drawbacks

The deepest 1-year drawdown on record here is 31.0%.

Who may consider ONC — and who may not

It is a weaker fit for investors who need monthly cash flow (ONC does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ONC

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions